Skip to main content

Table 1 Description of included trials

From: SCORE-IT (Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes): a systematic review of registered trials

  n (%)
Year
2009 1 (1)
2010 0 (0)
2011 2 (1)
2012 3 (2)
2013 6 (4)
2014 21 (15)
2015 49 (36)
2016 56 (41)
Phase
3 48 (35)
4 90 (65)
Planned enrolment (median and range) 135 (12–5000)
Region of worka
Asia 55 (40)
Europe 45 (33)
North America 46 (33)
South America 8 (6)
Africa 6 (4)
Central America 4 (3)
Australia 1 (1)
Not reported 6 (4)
Trial design
Parallel 125 (91)
Crossover 11 (8)
Other 2 (1)
Type of intervention
Drug 137 (92)
Placebo 83 (60)
Active drug 36 (26)
Usual care 1 (1)
Other 7 (5)
Education or lifestyle 3 (2)
Nutrition 6 (4)
Device 2 (1)
Duration of follow-up (median and range)b 24 (0–364) weeks
  1. aNumber exceeds total as a number of studies were conducted across multiple geographical areas
  2. b0 weeks = < 24-h follow-up (n = 3)